The U.S. Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA) has agreed to purchase (for storage and deployment in mass casualty or other emergency situations) AVITA Therapeutics’ (RCEL -8.5%) Recell System, a device that treats thermal burns with spray-on skin cells.
BARDA’s vendor-managed inventory plan is valued at $7.6M with an additional $1.6M available to support emergency deployment.
